Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn's disease: results of 2 Phase 2b randomised placebo-controlled trials

被引：0
|
作者：
Panes, J. [1 ]
Moscariello, M. [2 ]
Maller, E. [2 ]
Chan, G. [2 ]
Wang, W. [2 ]
Healey, P. [3 ]
机构：
[1] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Groton, CT 06340 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP053
引用
收藏
页码：S60 / S61
页数：2
相关论文
共 50 条
  • [1] Effects of Oral Tofacitinib on Patient-Reported Outcomes in Patients With Moderate to Severe Crohn's Disease: Results of Two Phase 2B Randomized Placebo-Controlled Trials
    Panes, Julian
    Chan, Gary
    Maller, Eric
    Moscariello, Michele
    Wang, Wenjin
    Healey, Paul J.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1003 - S1003
  • [2] Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohn's disease: results of a Phase 2b randomised placebo-controlled trial
    D'Haens, G.
    Pannaccione, R.
    Higgins, P. D. R.
    Colombel, J. -F.
    Feagan, B. G.
    Moscariello, M.
    Chan, G.
    Healey, P.
    Niezychowski, W.
    Wang, W.
    Marren, A.
    Maller, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S17 - S18
  • [3] Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn's disease: results of a Phase 2b randomised placebo-controlled trial
    Panes, J.
    Sandborn, W. J.
    Schreiber, S.
    Sands, B. E.
    Vermeire, S.
    Chan, G.
    Moscariello, M.
    Wang, W.
    Niezychowski, W.
    Marren, A.
    Healey, P.
    Maller, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S18 - S19
  • [4] Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial
    Panes, Julian
    Sandborn, William
    Schreiber, Stefan
    Sands, Bruce E.
    Vermeire, Severine
    Chan, Gary
    Moscariello, Michele
    Wang, Wenjin
    Niezychowski, Wojciech
    Marren, Amy
    Healey, Paul J.
    Maller, Eric
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S182 - S183
  • [5] Upadacitinib improved patient-reported pruritus in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial
    Hong, C. -H.
    Wu, T.
    Calimlim, B.
    Teixeira, H.
    de Bruin-Weller, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 10 - 10
  • [6] Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis
    Mamolo, C.
    Harness, J.
    Tan, H.
    Menter, A.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (02) : 192 - 203
  • [7] Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials
    Wallenstein, G. V.
    Kanik, K. S.
    Wilkinson, B.
    Cohen, S.
    Cutolo, M.
    Fleischmann, R.
    Genovese, M. C.
    Gomez Reino, J.
    Gruben, D.
    Kremer, J.
    Krishnaswami, S.
    Lee, E. B.
    Pascual-Ramos, V.
    Strand, V.
    Zwillich, S. H.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : 430 - 442
  • [8] LEBRIKIZUMAB IMPROVES CLINICAL MANIFESTATIONS AND PATIENT-REPORTED OUTCOMES IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: PHASE 2B STUDY RESULTS
    Ali, Z.
    Guttman-Yassky, E.
    Blauvelt, A.
    Eichenfield, L.
    Paller, A.
    Armstrong, A.
    Drew, J.
    Gopalan, R.
    Simpson, E.
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 32 - 32
  • [9] Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
    Panes, Julian
    Sandborn, William J.
    Schreiber, Stefan
    Sands, Bruce E.
    Vermeire, Severine
    D'Haens, Geert
    Panaccione, Remo
    Higgins, Peter D. R.
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Chan, Gary
    Moscariello, Michele
    Wang, Wenjin
    Niezychowski, Wojciech
    Marren, Amy
    Healey, Paul
    Maller, Eric
    [J]. GUT, 2017, 66 (06) : 1049 - 1059
  • [10] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Landers, Carol
    Li, Dalin
    Russell, Chris
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Hsu, Yi-Hsiang
    Lin, Shao-Lee
    Klekotka, Paul
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11): : 1599 - 1607
12345